Scinai gets Nasdaq minimum bid-price warning
Rhea-AI Filing Summary
Scinai Immunotherapeutics Ltd. reported that it received a written notice from the Nasdaq Listing Qualifications Department on March 12, 2026 stating that its American Depositary Shares are not in compliance with the Nasdaq Capital Market’s minimum bid price requirement, because the closing bid price was below $1.00 for 30 consecutive business days.
The notice does not immediately affect the listing or trading of the ADSs. Scinai has 180 calendar days, until September 8, 2026, to regain compliance, which will occur if the closing bid price is at least $1.00 for a minimum of ten consecutive business days. The company plans to monitor its share price and evaluate options to regain compliance.
Positive
- None.
Negative
- Nasdaq minimum bid price deficiency: The company’s ADSs traded below $1.00 for 30 consecutive business days, triggering a Nasdaq notice of non-compliance and a 180-day deadline to regain compliance.
Insights
Nasdaq minimum bid-price deficiency puts listing status under pressure.
Scinai Immunotherapeutics has fallen out of compliance with Nasdaq’s minimum $1.00 bid price rule after its ADSs traded below that level for 30 consecutive business days. This type of notice is a standard early-stage warning under Nasdaq’s continued listing requirements.
Nasdaq has granted a 180-day grace period, until September 8, 2026, for the company to regain compliance. Compliance would be restored if the closing bid price reaches at least $1.00 for ten consecutive business days. The notice itself does not immediately affect trading or listing.
The company states it will monitor the ADS closing price and evaluate available options to regain compliance. Concrete steps are not detailed here, so subsequent company filings or announcements will be needed to understand any specific actions taken within this compliance window.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Scinai Immunotherapeutics (SCNI) disclose in its March 2026 6-K?
Why did Nasdaq issue a minimum bid price notice to Scinai Immunotherapeutics (SCNI)?
How long does Scinai Immunotherapeutics (SCNI) have to regain Nasdaq bid price compliance?
Does the Nasdaq notice immediately affect trading of Scinai Immunotherapeutics (SCNI) ADSs?
What options is Scinai Immunotherapeutics (SCNI) considering to regain Nasdaq compliance?
What business does Scinai Immunotherapeutics (SCNI) focus on despite the Nasdaq notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of March 2026
Commission File Number: 001-37353
SCINAI IMMUNOTHERAPEUTICS LTD.
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Explanatory Note
On March 16, 2026, Scinai Immunotherapeutics Ltd. issued a press release announcing receipt of Nasdaq notification regarding its minimum bid price.
A copy of the press release is furnished herewith as Exhibit 99.1.
This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-291460, 333-271293 and File No. 333-239344) and Form F-3 (File No. 333-274078 and File No. 333-276767), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
Exhibit Index
| Exhibit No. | Description | |
| 99.1 | Press release dated March 16, 2026. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Scinai Immunotherapeutics Ltd. | ||
| Date: March 19, 2026 | By: | /s/ Amir Reichman |
| Amir Reichman | ||
| Chief Executive Officer | ||
3
Exhibit 99.1
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares (“ADSs”) was below $1.00 per share for 30 consecutive business days.
The notification has no immediate effect on the listing or trading of the Company’s ADSs on the Nasdaq Capital Market.
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until September 8, 2026, to regain compliance with the minimum bid price requirement. If at any time during this period the closing bid price of the ADSs is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.
The Company will continue to monitor the closing bid price of its ADSs and evaluate available options to regain compliance with the Nasdaq minimum bid price requirement.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.
Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.
Company website: www.scinai.com
Company Contacts
Investor Relations - Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the Company’s ability to regain compliance with the Nasdaq minimum bid price requirement and the Company’s evaluation of available options to achieve such compliance. Words such as “expects,” “intends,” “plans,” “believes,” “may,” “will,” “anticipates,” “estimates,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, market conditions affecting the trading price of the American Depositary Shares and the Company’s ability to meet the continued listing requirements of The Nasdaq Capital Market. More detailed information regarding these and other risks and uncertainties is included under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on May 7, 2025, and in the Company’s subsequent filings with the SEC.
Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg